# US 2001/0027174 A1 · Neo-tryptophan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027174 A1
- Document ID: US20010027174A1
- Status: Published application
- Kind: A1
- Application number: 09/755,638
- Filed: 2001-01-05
- Published: 2001-10-04
- Earliest claimed: 1998-04-10
- Assignees: Mayo Foundation for Medical Education and Research, a Minnesota corporation
- Inventors: Elliott Richelson; Bernadette Marie Cusack; Yuan-Ping Pang; Daniel J. McCormick; Abdul Fauq; Beth Marie Tyler; Mona Boules
- Web page: https://patentgrep.com/patent/US20010027174A1

## CPC

- C07K 7/083: {Neurotensin}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07K 7/14: Angiotensins: Related peptides
- C07K 7/18: Kallidins; Bradykinins; Related peptides
- C07K 14/70: Enkephalins
- C07K 14/702: {with at least 1 amino acid in D-form}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.

## Claims

### Claim 1

A polypeptide, wherein said polypeptide comprises neo-tryptophan.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide is substantially pure.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein said neo-tryptophan is L-neo-tryptophan.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein said neo-tryptophan is D-neo-tryptophan.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide interacts with a neurotensin receptor.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide is a neurotensin analog with neo-tryptophan being located at amino acid position 11 of neurotensin.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide is selected from the group consisting of NT64D, NT64L, NT65L, NT66D, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, NT77, Angl, Brdyl, and Lenkl.

### Claim 8

An amino acid, wherein said amino acid is neo-tryptophan.

### Claim 9 (depends on 8)

The amino acid of claim 8, wherein said amino acid is substantially pure.

### Claim 10 (depends on 8)

The amino acid of claim 8, wherein said amino acid is L-neo-tryptophan.

### Claim 11 (depends on 8)

The amino acid of claim 8, wherein said amino acid is D-neo-tryptophan.

### Claim 12

A neo-tryptophan derivative.

### Claim 13 (depends on 12)

The neo-tryptophan derivative of claim 12, wherein said derivative comprises neo-tryptophan and a blocking group.

### Claim 14 (depends on 13)

The neo-tryptophan derivative of claim 13, wherein said blocking group comprises Fmoc.

### Claim 15 (depends on 13)

The neo-tryptophan derivative of claim 13, wherein said blocking group comprises Boc.

### Claim 16

A serotonin-like neo-tryptophan derivative, said derivative comprising the following structure: 2
wherein R1, R2, and R3 is H, OH, CH3, SH, F, NH2, or COOH, and A is zero, one, two, or three.

### Claim 17 (depends on 16)

The serotonin-like neo-tryptophan derivative of claim 16, wherein R1 and R3 each is a hydroxyl group, R2 is an amino group, and A is zero.

### Claim 18

A method of synthesizing neo-tryptophan, said method comprising:
a) providing 4-hydroxymethyl indole, and
b) substituting the hydroxyl group of said 4-hydroxymethyl indole with a glycyl unit to produce neo-tryptophan.

### Claim 19 (depends on 18)

The method of claim 18, wherein the N-1 nitrogen of said 4-hydroxymethyl indole is protected by a protecting group, said method comprising removing said protecting group after said substitution.

### Claim 20 (depends on 19)

The method of claim 19, wherein said protecting group comprises Boc.

### Claim 21 (depends on 18)

The method of claim 18, wherein said method comprises:
a) providing 2-methyl-3-nitrobenzoic acid,
b) esterifying said 2-methyl-3-nitrobenzoic acid to form an esterification product,
c) reacting said esterification product with N,N-dimethylformamide dimethylacetal to produce an enamine product,
d) performing reductive cyclization on said enamine product to produce a 4-substituted indole methyl ester,
e) protecting the indole nitrogen of said 4-substituted indole methyl ester with a Boc group,
f) reducing said protected 4-substituted indole methyl ester with DIBAL to produce N-Boc-4-hydroxymethyl indole,
g) converting said N-Boc4-hydroxymethyl indole into benzylic bromide,
h) performing SN2 displacement of the bromide of said benzylic bromide with a carbanion to produce diastereomeric bislactim products,
i) isolating one of said diastereomeric bislactim products,
j) hydrolyzing said isolated diastereomeric bislactim product to produce an aminoester product,
k) saponifying said aminoester product to produce an Nind-t-Boc amino acid, and
l) removing the Boc group to produce neo-tryptophan.

### Claim 22

A method of synthesizing a neo-tryptophan derivative, said method comprising:
a) providing 4-hydroxymethyl indole, wherein the N-1 nitrogen of said 4-hydroxymethyl indole is protected by a protecting group, and
b) substituting the hydroxyl group of said 4-hydroxymethyl indole with a glycyl unit to produce a neo-tryptophan derivative.

### Claim 23 (depends on 22)

The method of claim 22, wherein said protecting group comprises Boc.

### Claim 24 (depends on 22)

The method of claim 22, wherein said method comprises adding, after said substitution, an additional protecting group to the nitrogen within said glycyl unit.

### Claim 25 (depends on 24)

The method of claim 24, wherein said additional protecting group comprises Fmoc.

### Claim 26

A method of making a polypeptide containing neo-tryptophan, said method comprising:
a) providing a neo-tryptophan derivative, and
b) linking an amino acid residue to said neo-tryptophan derivative to form said polypeptide containing neo-tryptophan.

### Claim 27 (depends on 26)

The method of claim 26, wherein said neo-tryptophan derivative contains a blocking group attached to a nitrogen atom.

### Claim 28 (depends on 26)

The method of claim 26, wherein said neo-tryptophan is L-neo-tryptophan.

### Claim 29 (depends on 26)

The method of claim 26, wherein said neo-tryptophan is D-neo-tryptophan.

### Claim 30

A method of inducing a neurotensin response in a mammal, said method comprising administering an effective dose of a polypeptide to said mammal, wherein said polypeptide comprises neo-tryptophan.

### Claim 31 (depends on 30)

The method of claim 30, wherein said mammal is a human.

### Claim 32 (depends on 30)

The method of claim 30, wherein said administration is extracranial.

### Claim 33 (depends on 30)

The method of claim 30, wherein said administration is an intraperitoneal, intravenous, intradermal, subcutaneous, oral, or nasal administration.

### Claim 34 (depends on 30)

The method of claim 30, wherein said response comprises antinociception.

### Claim 35 (depends on 30)

The method of claim 30, wherein said response comprises hypothermia.

### Claim 36 (depends on 30)

The method of claim 30, wherein said response comprises a reduction in appetite.

### Claim 37 (depends on 30)

The method of claim 30, wherein said response comprises a reduction in body weight.

### Claim 38 (depends on 30)

The method of claim 30, wherein said response comprises a reduction in body weight gain.

### Claim 39 (depends on 30)

The method of claim 30, wherein said response comprises preventing or reducing catalepsy.

### Claim 40 (depends on 30)

The method of claim 30, wherein said response comprises reducing an effect of a CNS stimulant.

### Claim 41 (depends on 40)

The method of claim 40, wherein said CNS stimulant comprises apomorphine.

### Claim 42 (depends on 41)

The method of claim 41, wherein said effect comprises a climbing behavior.

### Claim 43 (depends on 40)

The method of claim 40, wherein said CNS stimulant is selected from the group consisting of amphetamine and cocaine.

### Claim 44 (depends on 30)

The method of claim 30, wherein said response comprises an antipsychotic effect.

### Claim 45 (depends on 44)

The method of claim 44, wherein said polypeptide reduces the signs or symptoms of schizophrenia in said mammal.

### Claim 46 (depends on 30)

The method of claim 30, wherein said polypeptide interacts with a neurotensin receptor.

### Claim 47 (depends on 46)

The method of claim 46, wherein said neurotensin receptor is a rat neurotensin receptor.

### Claim 48 (depends on 46)

The method of claim 46, wherein said neurotensin receptor is a human neurotensin receptor.

### Claim 49 (depends on 30)

The method of claim 30, wherein said polypeptide is selected from the group consisting of NT64D, NT64L, NT65L, NT66D, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, and NT77.

### Claim 50

A method of treating a mammal having a serotonin recognition molecule, said method comprising administering a composition to said mammal, wherein said composition interacts with said serotonin recognition molecule, said composition comprising a compound selected from the group consisting of neo-tryptophan, neo-tryptophan derivatives, and serotonin-like neo-tryptophan derivatives.

### Claim 51 (depends on 50)

The method of claim 50, wherein said mammal is a human.

### Claim 52 (depends on 50)

The method of claim 50, wherein said composition comprises a polypeptide.

### Claim 53 (depends on 50)

The method of claim 50, wherein said serotonin recognition molecule comprises a serotonin receptor.

### Claim 54 (depends on 53)

The method of claim 53, wherein said serotonin receptor is a 5HT2A receptor.

### Claim 55

A method for screening a polypeptide for in vivo use, said method comprising:
a) contacting a polypeptide with a protease, wherein said polypeptide contains neo-tryptophan, and
b) determining whether or not said polypeptide remains intact.

### Claim 56

The use of a polypeptide in the manufacture of a medicament for treating a mammal, said polypeptide comprising neo-tryptophan.

### Claim 57

The use of a compound in the manufacture of a medicament for treating a mammal, said compound being selected from the group consisting of neo-tryptophan, neo-tryptophan derivatives, and serotonin-like neo-tryptophan derivatives.
